This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence:
MGC Pharmaceuticals has just released their first product to the market.
I’m very excited to announce the release of CannEpil™, a product that has been years in the making. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.
We have been working hard testing the effects of CBD on patients with epilepsy, with our advisory team, Professor Uri Kramer and Professor David Neubauer, for the past two years.
All this hard work has led to the release of CannEpil™, which we couldn’t be more excited about, not just for MGC Pharma, but also for the many people suffering from severe epilepsy and seizures across the world.
According to the World Health Organisation (WHO), there are roughly 50 million people in the world with some form of epilepsy, and of those 50 million, 30% have refractory epilepsy.
Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CBD has recently been proven to reduce the severity of seizures, which is another reason we are so excited to release CannEpil™ into the market.
For a long time, it has been MGC Pharma’s vision to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and become a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.
The release of CannEpil™ is our first step toward achieving this vision. And with many more products in the pipeline at MGC Pharma, we look forward to releasing many more products in the future that will continue to provide solutions to previously unmet medical needs and improve the lives of millions of people.